Interpace Biosciences, Inc. booked $38.7M in FY2025 revenue, contracting 17% year over year — slower than 72% of Healthcare companies we track, at a 63.5% net margin.
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.